MA Audit: 13% of Cannabis Flower Fails THC Accuracy Test

August 25, 2026

Photo by MART PRODUCTION via Pexels.

Massachusetts built one of the country's more mature legal cannabis markets on a simple promise: what's on the label is what's in the bag. A patient managing chronic pain who buys an eighth labeled at 22% THC is trusting that number to plan a dose, not rolling dice. That promise just took a visible hit. The Cannabis Control Commission ran its first-ever shelf audit of flower products already sitting in dispensaries across the state, and the results landed on a market now valued at roughly $1.7 billion in annual sales. For an industry that size, a labeling problem isn't a rounding error -- it's a trust problem, and trust is the only thing keeping customers out of the unregulated market entirely.

What the Audit Found

Photo by RDNE Stock project via Pexels.

Starting in May 2026, the CCC pulled 63 flower products from 62 different producers directly off retail and medical dispensary shelves, then sent them out for independent verification testing rather than relying on the numbers producers had already submitted. The goal was blunt: check whether what's printed on the package actually matches what's in the jar, using product that real customers were actively buying, not samples cherry-picked in a lab setting.

The Commission's accuracy standard gives producers a fairly generous window. A label is considered compliant if the verified THC result falls between 75% and 125% of the stated potency. So a package marked 15% THC passes as long as retesting comes back anywhere between 11.25% and 18.75% total THC. That's not a tight scientific tolerance -- it's a practical one, built to account for natural variation in flower and differences between testing equipment.

Even with that cushion, the results split into a color-coded scorecard that tells a fairly uncomfortable story. Green covered the high-accuracy tier, yellow flagged products sitting close to the edge of the acceptable range, and red marked products that fell outside it entirely. Thirteen products landed in the red, meaning they failed to meet even the loosened standard. Another 43 came back yellow, technically compliant but close enough to the line that a slightly different testing run might have pushed them into noncompliance. Only seven products out of the 63 tested within 2% of their labeled potency, the tightest accuracy tier the Commission tracked. That means the products consumers can trust with real confidence were a small minority of what got checked.

How the Investigation Started

Photo by Lucas Vasques via Unsplash.

The audit didn't come out of nowhere. It followed a bulletin issued in May by the CCC's Investigations and Enforcement Department, part of a broader internal testing task force the Commission stood up specifically to deal with concerns about testing integrity in the state's licensed lab network. Regulators had already seen enough red flags to know flower potency deserved a direct, retail-level check rather than another round of paperwork review.

That task force has a track record worth noting. Its earlier and more dramatic action was a Summary Suspension Order against Assured Testing Laboratories, one of the state's licensed testing facilities, over findings that test results had been falsified. That case didn't just fade away -- it ended in a stipulated agreement that included a financial penalty and a mandated overhaul of the lab's personnel and internal policies, a signal that the Commission was willing to shut down a lab's operations mid-stream if the data coming out of it couldn't be trusted.

Massachusetts's entire compliance system rests on a network of ten Independent Testing Laboratories, known as ITLs, which are responsible for verifying THC content along with screening for contaminants like pesticides, heavy metals, and microbial growth before product ever reaches a shelf. When confidence in that network wavers, the Commission's only real option is to go around it and check the finished product directly -- which is exactly what this flower audit did.

What Happens to the Noncompliant Products

Photo by Rohit Choudhari via Unsplash.

For the 13 producers whose products landed in the red zone, the consequences are immediate and concrete. Those products are now under administrative hold, which blocks any further sales until the situation gets resolved. The Commission has laid out several paths forward, and producers don't get to simply argue the point -- they have to act. Options include recalling the flower and repurposing it into another form after new testing, recalling and relabeling it with the corrected numbers from the audit, submitting it for another round of retesting, or destroying it outright if none of those options are viable.

Dispensaries themselves aren't just waiting on instructions from producers, either. They have discretion of their own to pull flagged products off shelves or destroy them proactively, even before a producer's follow-up plan is finalized. That matters for a patient walking into a shop this week -- a product that was on the shelf last month could simply be gone now, with no need for the retailer to wait on a formal recall notice.

The Commission began notifying affected producers this past Thursday, and it says additional notices will continue going out on a rolling basis as follow-up reviews wrap up. Worth remembering: this was the first shelf audit of its kind ever conducted in Massachusetts. There's no historical baseline to compare it against, which makes it hard to say whether a 13% noncompliance rate represents an improvement, a decline, or simply the first honest look at a problem that's existed all along.

Regulators' Response and What's Next

Of the 63 Massachusetts flower products audited, the majority (43) had THC levels near the edge of the acceptable range, while only 7 were within 2% of the label and 13 tested outright outside the acceptable variation.

CCC Executive Director Travis Ahern framed the audit as a direct extension of the internal testing task force's founding mission -- overseeing a marketplace that's both safe and equitable, not just profitable. He's also been clear that this isn't a one-off exercise. The results from this round will help the Commission calibrate how it structures future audits, as it moves toward a system of random testing that would cover not just potency but contaminants like pesticides, heavy metals, yeast, mold, and bacteria across the broader product supply.

CCC Chair Chris Harding has put the issue in more human terms, framing accurate labeling as fundamentally a health and safety matter rather than a marketing technicality. That framing lands hardest for medical patients, many of whom titrate their doses specifically around a labeled potency number -- a mismatch between label and reality isn't just a consumer-protection annoyance for them, it's a real clinical variable.

The audit also arrives alongside a couple of other regulatory moves worth watching. The Commission has started requiring digital Certificates of Analysis to be uploaded directly into the state's seed-to-sale tracking system, closing off some of the paperwork gaps that made falsified results easier to slip through in the first place. It's also launched a new Public Health and Safety Advisories portal, giving the public a direct window into recalls and enforcement actions rather than relying on producers or retailers to pass that information along. Taken together, these moves point toward a regulator that's trying to get ahead of problems with its own data rather than waiting for complaints to trigger an investigation.

None of this means Massachusetts's market is unusually broken -- it means Massachusetts is one of the few states willing to actually look. Plenty of legal markets around the country have never run a comparable shelf audit, which doesn't mean their labels are more accurate, just that nobody has checked with this level of rigor. The honest takeaway for any consumer, in any state, is to treat a THC percentage on a flower label as a reasonable estimate rather than a guaranteed figure, particularly for products sitting near the low or high end of a strain's typical range.

If you're dosing for medical reasons, that distinction matters even more. It's worth finding out whether your state's cannabis regulator publishes lab results, recall notices, or public advisories the way Massachusetts now does, and checking that resource before assuming a label tells the whole story. Regulations and enforcement practices vary significantly from state to state, so confirm the rules and available consumer protections where you actually live before making decisions based on what you read here.